IT1221487B - Bi:phenyl-methoxy hydroxy-piperidino cyclopentyl heptenoic acid salt - Google Patents
Bi:phenyl-methoxy hydroxy-piperidino cyclopentyl heptenoic acid saltInfo
- Publication number
- IT1221487B IT1221487B IT48979/83A IT4897983A IT1221487B IT 1221487 B IT1221487 B IT 1221487B IT 48979/83 A IT48979/83 A IT 48979/83A IT 4897983 A IT4897983 A IT 4897983A IT 1221487 B IT1221487 B IT 1221487B
- Authority
- IT
- Italy
- Prior art keywords
- doses
- cyclopentyl
- heptenoic acid
- inhalation
- hydrogen chloride
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 abstract 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 abstract 1
- 206010050902 Postoperative thrombosis Diseases 0.000 abstract 1
- 208000010378 Pulmonary Embolism Diseases 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 abstract 1
Abstract
(1R-(1alpha(Z), 2beta, 3beta, 5alpha)) -(+)-7-(5-(((1,1'-biphenyl)4-yl)methoxy) -3-hydroxy-2-(1-piperidinyl)cyclopentyl)-4-heptenoic acid hydrochloride (A) is new. By treatment of the corresponding aminoacid or an appropriate ester (e.g. the ethyl ether) with hydrochloric acid or hydrogen chloride, e.g. a soln. of the aminoacid is treated with hydrogen chloride, using a solvent such as ether, CH2Cl2, ethyl acetate or dimethoxyethane at 0 deg. C to room temp. Endoperoxide (prostaglandins G2 and H2) and thromboxane A2 antagonist, which inhibits thrombo-agglutination and bronchoconstriction and is used to treat asthma and cardiovascular troubles. Cpd. A may be used in renal dialysis, for treatment of vascular occlusive problems, such as arteriosclerosis, atherosclerosis, peripheral and cerebral vascular troubles, ischaemic attacks, pulmonary embolism, diabetic retinopathy, post operative thromboses, angina pectoris and myocardial infarctus. (A) may be administered orally, parenterally or by inhalation. As an antithrombotic it is used orally in doses of 0.05-5 mg/Kg (unit doses of 3.5-350 mg) administered 1-4 times daily. Inhalation doses are 0.3-30 mg, 1-4 times daily.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8127982 | 1981-09-16 | ||
| GB8132675 | 1981-10-29 | ||
| GB8212489 | 1982-04-29 | ||
| GB8213069 | 1982-05-06 | ||
| GB08226378A GB2108116B (en) | 1981-09-16 | 1982-09-16 | Aminocyclopentane esters and their preparation and pharmaceutical formulation |
| GB8230771 | 1982-10-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IT8348979A0 IT8348979A0 (en) | 1983-09-15 |
| IT1221487B true IT1221487B (en) | 1990-07-06 |
Family
ID=27546802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT48979/83A IT1221487B (en) | 1981-09-16 | 1983-09-15 | Bi:phenyl-methoxy hydroxy-piperidino cyclopentyl heptenoic acid salt |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT1221487B (en) |
-
1983
- 1983-09-15 IT IT48979/83A patent/IT1221487B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| IT8348979A0 (en) | 1983-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2549801A1 (en) | Use of treprostinil to improve kidney functions | |
| RU98117511A (en) | NEW ACTIVE BEGINNING COMPOUNDS CONTAINING CLOPIDOGEL AND ANTITROMBIC MEDICINE | |
| CH642549A5 (en) | POLYSALINIC SOLUTION FOR HEMODIALYSIS, CONTAINING CARNITINE. | |
| Anderson et al. | Successful treatment by overdrive pacing of recurrent quinidine syncope due to ventricular tachycardia | |
| WO1993014761A1 (en) | Prostacyclin and carbacyclin derivatives as agents in the treatment of multiple sclerosis | |
| US5861434A (en) | Compositions containing L-carnitine or an acyl L-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders | |
| Lewis et al. | Verapamil in the management of hypertensive patients | |
| IT1221487B (en) | Bi:phenyl-methoxy hydroxy-piperidino cyclopentyl heptenoic acid salt | |
| AU660449B2 (en) | Prostacycline and carbacycline derivatives as agents for treating feverish complaints | |
| Szekely et al. | Direct current shock and antidysrhythmic drugs | |
| VanderArk et al. | Quinidine syncope: A report of successful treatment with bretylium tosylate | |
| EP0759297B1 (en) | Remedy for pulmonary heart | |
| EP0129908A1 (en) | Use of misoprostol to manufacture cholesterol lowering medicines | |
| EP0485748B1 (en) | Salts of glycosaminoglycans with esters of aminoacids, preparation thereof and pharmaceutical formulations containing them | |
| Hunninghake et al. | Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide | |
| Saarnivaara et al. | Effects of practolol and metoprolol on QT interval, heart rate and arterial pressure during induction of anaesthesia | |
| Naudé et al. | Studies on South African cardiac glycosides. II. Observations on the clinical and haemodynamic effects of cotyledoside | |
| Svedmyr | Effects of Oral Theophylline Combined with Oral and Inhaled β2‐Adrenostimulants in Asthmatics | |
| AU735975B2 (en) | Remedy for pulmonary heart | |
| NO803918L (en) | PROCEDURE FOR THE MANUFACTURE OF NEW ESTERS OF ARGININE | |
| Rutsky | Bradycardic rhythms during peritoneal dialysis | |
| SU1747071A1 (en) | Method for treating the cases of acute myocardial infarction | |
| Wang et al. | Augmented pressor response to vasopressin in awake dogs after cardiac denervation | |
| Persson | The antihypertensive effect of pindolol (Visken) alone and combined with clopamide (Brinaldix) | |
| Green et al. | Alpha-methyltyrosine in the management of phaeochromocytoma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19950928 |